Q-omics provides the consensus-scored MTMR6 profile across patient tissues and cancer cell-line models. MTMR6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MTMR6 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, MTMR6 protein abundance shows 26,189 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where MTMR6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTMR6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTMR6 survival associations across molecular data types. MTMR6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTMR6 RNA expression–survival associations across cancer types. High MTMR6 expression shows unfavorable associations in CESC, but favorable associations in KIRC, COAD, UCEC, BRCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MTMR6 RNA expression.
This table summarizes MTMR6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 8. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MTMR6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTMR6 shows lower tumor expression in KICH, LUSC, THCA and LUAD and higher tumor expression in LIHC and CHOL. The KICH box plot shows higher MTMR6 RNA expression in normal versus tumor tissue (log2 FC = −1.721, t-test p < 0.001).
This table shows molecular features associated with MTMR6 in patient tissues and cancer cell lines. In patient samples, MTMR6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MTMR6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
